Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| PT-141 (Bremelanotide) | Tesamorelin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity. | Research indicates 2 mg administered once daily via subcutaneous injection (FDA-approved dose for HIV lipodystrophy). |
| Timing | 45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response. | Morning administration on empty stomach. Consistent daily timing recommended. |
| Cycle Duration | As-needed basis. Not intended for daily use. | 26+ weeks in clinical trials. Long-term use is common; effects are not sustained after discontinuation. |
| Evidence Level | strong_human | Strong (FDA-approved indication), Moderate (longevity) |
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin analog that acts as an agonist at MC3R and MC4R melanocortin receptors, with higher affinity for MC4R. It enhances sexual desire by activating presynaptic MC4Rs on neurons in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release — an excitatory neurotransmitter for sexual desire. Unlike PDE5 inhibitors, PT-141 works centrally through the CNS rather than peripherally on blood flow, addressing desire rather than just erectile mechanics.
Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.
45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.
As-needed basis. Not intended for daily use.
Tesamorelin is an FDA-approved synthetic 44-amino acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminal tyrosine that confers resistance to DPP-IV degradation. It binds GHRH receptors on anterior pituitary somatotrophs, stimulating endogenous GH production and secretion while maintaining pulsatile release patterns. Tesamorelin selectively reduces visceral adipose tissue (15-20% reduction in trials) while preserving subcutaneous fat, and markedly increases plasma GH and IGF-1 levels with once-daily dosing.
Research indicates 2 mg administered once daily via subcutaneous injection (FDA-approved dose for HIV lipodystrophy).
Morning administration on empty stomach. Consistent daily timing recommended.
26+ weeks in clinical trials. Long-term use is common; effects are not sustained after discontinuation.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →